Akari Therapeutics Plc
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
AKTX$7.13-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders' Equity (Deficit)
Condensed Cons olidated Statements of Changes in Shareholders’ Equity (Deficit)
(amounts in thousands, except share data)
| Accumulated | |||||||
|---|---|---|---|---|---|---|---|
| Additional · Capital · Other · Total | |||||||
| Share Capital $0.0001 par value · Paid-in- · Redemption · Comprehensive · Accumulated · Shareholders' | |||||||
| Shares | Amount | Capital | Reserve | Loss | Deficit | Equity | |
| Balance, December 31, 2024 | 53,186,919,523 | $5,319 | $212,706 | $52,194 | $(738) | $(247,252) | $22,229 |
| Issuance of share capital related to financing, net of issuance costs | 4,566,062,000 | 457 | 1,785 | — | — | — | 2,242 |
| Stock-based compensation | — | — | 1,015 | — | — | — | 1,015 |
| Foreign currency translation | — | — | — | — | (35) | — | (35) |
| Net loss | — | — | — | — | — | (3,705) | (3,705) |
| Balance, March 31, 2025 | 57,752,981,523 | $5,776 | $215,506 | $52,194 | $(773) | $(250,957) | $21,746 |
| Accumulated | |||||||
|---|---|---|---|---|---|---|---|
| Additional · Capital · Other · Total | |||||||
| Share Capital $0.0001 par value · Paid-in- · Redemption · Comprehensive · Accumulated · Shareholders' | |||||||
| Shares | Amount | Capital | Reserve | (Income) Loss | Deficit | Equity (Deficit) | |
| Balance, December 31, 2023 | 13,234,315,298 | $1,324 | $174,754 | $52,194 | $(1,040) | $(227,461) | $(229) |
| Issuance of share capital related to financing, net of issuance costs | 2,641,228,000 | 264 | 1,400 | — | — | — | 1,664 |
| Vesting of restricted shares | 97,578,000 | 10 | (7) | — | — | — | 3 |
| Stock-based compensation | — | — | 296 | — | — | — | 296 |
| Foreign currency translation | — | — | — | — | 279 | — | 279 |
| Net loss | — | — | — | — | — | (5,566) | (5,566) |
| Balance, March 31, 2024 | 15,973,121,298 | $1,598 | $176,443 | $52,194 | $(761) | $(233,027) | $(3,553) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.